Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 80

Sort by

Sort Order Select

Journal Articles

Targeted interferon therapy with modakafusp alfa for relapsed or refractory multiple myeloma

Dan T. Vogl, Shebli Atrash, Sarah A. Holstein, Omar Nadeem, Don Benson, Maria Chaudry, Noa Biran, Kaveri Suryanarayan, Cheryl Li, Yuyin Liu, Sabrina Collins, Xavier Parot, Jonathan L. Kaufman

Blood (2025) 145 (9): 944–955.

https://doi.org/10.1182/blood.2024026124

Published: 2025

Includes: Supplemental data

Journal Articles

Enhanced Prognostic Value of the SKY92 Classifier over High-Risk Cytogenetic Aberrations in Multiple Myeloma: Results from the Prommis Real-World Study

Noa Biran, Binod Dhakal, Ruben Niesvizky, Suzanne Lentzsch, John T Mckay, David H. Vesole, Ajay K. Nooka, Barry Paul, Parameswaran N. Hari, Silvia D'Ambrosi, Rowan Kuiper, Martin H van Vliet, David S. Siegel, Saad Z. Usmani, Frits van Rhee

Blood (2024) 144 (Supplement 1): 1929.

https://doi.org/10.1182/blood-2024-209903

Published: 2024

Journal Articles

Phase 2 Registrational Study of Anitocabtagene Autoleucel for the Treatment of Patients with Relapsed and/or Refractory Multiple Myeloma: Preliminary Results from the IMMagine-1 Trial

Blood (2024) 144 (Supplement 1): 1031.

https://doi.org/10.1182/blood-2024-198499

Published: 2024

Journal Articles

Efficacy and Safety of Selinexor, Pomalidomide, and Dexamethasone (SPd) for Treatment of Patients with Relapsed or Refractory Multiple Myeloma (RRMM)

Muhamed Baljevic, Nizar J. Bahlis, Rami Kotb, Gary J. Schiller, Brea Lipe, Sumit Madan, Heather J. Sutherland, Suzanne Lentzsch, Natalie Callander, Noa Biran, Dane Van Domelen, Tomer Mark, Darrell White

Blood (2024) 144 (Supplement 1): 1996.

https://doi.org/10.1182/blood-2024-208086

Published: 2024

Journal Articles

Phase II Study of Isatuximab, and Weekly Carfilzomib + Dexamethasone in Relapsed and Refractory Multiple Myeloma (RRMM)

David H. Vesole, Thomas G Martin, Suzanne Trudel, Henning Schade, Samantha Shenoy, Noa Biran, Jeffrey Lee Wolf, Jeffrey V Matous, Pamela Munster, Savannah Berkeley, Jesús G Berdeja

Blood (2024) 144 (Supplement 1): 1982.

https://doi.org/10.1182/blood-2024-209597

Published: 2024

Journal Articles

Real World Outcomes of Multiple Myeloma Patients Who Underwent Apheresis for Planned Chimeric Antigen Receptor (CAR) T Cell Therapy: A Single Center Experience

Ayrton I Bangolo, Sarvarinder Kaur Gill, Behzad Amoozgar, Shraboni Dey, Ronit Slotky, David S. Siegel, Harsh Parmar, Noa Biran, David H. Vesole, Pooja Phull

Blood (2024) 144 (Supplement 1): 7097.

https://doi.org/10.1182/blood-2024-211895

Published: 2024

Journal Articles

Establishing a Distinct Cytokine Signature for Multiple Myeloma Using Bone Marrow RNA and Peripheral Blood Cell-Free RNA (cfRNA)

Maher Albitar, Hong Zhang, Sally Agersborg, Ahmad Charifa, Pooja Phull, Noa Biran, David H. Vesole, Harsh Parmar, Andrew L Pecora, Andrew Ip, Andre Goy, David S. Siegel

Blood (2024) 144 (Supplement 1): 3316.

https://doi.org/10.1182/blood-2024-203774

Published: 2024

Journal Articles

Clonotype-Naïve Detection of Clonality in Patients Suspected of Having Multiple Myeloma or Monoclonal Gammopathy Using Peripheral Blood Cell-Free RNA (cfRNA)

Maher Albitar, Hong Zhang, Sally Agersborg, Ahmad Charifa, Pooja Phull, Noa Biran, David H. Vesole, Harsh Parmar, Andrew L Pecora, Andrew Ip, Andre Goy, David S. Siegel

Blood (2024) 144 (Supplement 1): 1946.

https://doi.org/10.1182/blood-2024-201810

Published: 2024

Journal Articles

Delayed Neurotoxicity after CAR-T in Multiple Myeloma: Results from a Global IMWG Registry

Blood (2024) 144 (Supplement 1): 4758.

https://doi.org/10.1182/blood-2024-201783

Published: 2024

Journal Articles

Real World Outcomes with Talquetamab, a T-Cell-Redirecting GPRC5D Bispecific Antibody: A Single Center Experience for Relapsed/ Refractory Multiple Myeloma (RRMM)

Sarvarinder Kaur Gill, Erika Fleming, Helen Gebre, Ayrton I Bangolo, David S. Siegel, David H. Vesole, Noa Biran, Harsh Parmar, Pooja Phull

Blood (2024) 144 (Supplement 1): 7047.

https://doi.org/10.1182/blood-2024-210350

Published: 2024

Journal Articles

A Single-Center Experience on the Safety and Efficacy of Venetoclax-Based Regimens in Patients with Relapsed/Refractory Multiple Myeloma

Eli Zolotov, Vanisha Patel, Yedidyah Weiss, Noa Biran, Pooja Phull, David H. Vesole, David S. Siegel, Harsh Parmar

Blood (2024) 144 (Supplement 1): 6959.

https://doi.org/10.1182/blood-2024-194740

Published: 2024

Journal Articles

A Phase 2b Study of Selinexor in Combination with Pomalidomide in Patients with Pomalidomide-Refractory Multiple Myeloma

Blood (2024) 144 (Supplement 1): 7070.

https://doi.org/10.1182/blood-2024-208473

Published: 2024

Journal Articles

Repurposing DNA Methyltranferase Inhibitors As Epigenetic Priming Agents for T Cell Directed Therapies in Multiple Myeloma

Rena Feinman, Ariel Aptekmann, Iriana Colorado, Reilly Kobbe, Marta Salas, Noa Biran, David S. Siegel, Benjamin Tycko

Blood (2024) 144 (Supplement 1): 1888.

https://doi.org/10.1182/blood-2024-209229

Published: 2024

Journal Articles

Comparative Efficacy and Safety of Ciltacabtagene Autoleucel and Idecabtagene Vicleucel in Real-World Relapsed/Refractory Multiple Myeloma: A Retrospective Intention-to-Treat Analysis

Behzad Amoozgar, Ayrton I Bangolo, David H. Vesole, David S. Siegel, Noa Biran, Pooja Phull, Michele L. Donato, Harsh Parmar

Blood (2024) 144 (Supplement 1): 2408.

https://doi.org/10.1182/blood-2024-211671

Published: 2024

Journal Articles

Unveiling the Discrepancy in Multiple Myeloma Risk Classification between Clinical Practice and SKY92 Test and the Impact on Survival

Noa Biran, Binod Dhakal, Ruben Niesvizky, Suzanne Lentzsch, John T. McKay, David H. Vesole, Ajay K. Nooka, Barry Paul, Parameswaran N. Hari, Lisette Stork-Sloots, Silvia D'Ambrosi, Rowan Kuiper, Martin van Vliet, David S. Siegel, Saad Z Usmani, Frits van Rhee

Blood (2023) 142 (Supplement 1): 2013.

https://doi.org/10.1182/blood-2023-181905

Published: 2023

Journal Articles

Talquetamab + Pomalidomide in Patients with Relapsed/Refractory Multiple Myeloma: Safety and Preliminary Efficacy Results from the Phase 1b MonumenTAL-2 Study

Jeffrey Matous, Noa Biran, Aurore Perrot, Jésus G Berdeja, Kathleen Dorritie, Janine Van Elssen, Emma Searle, Cyrille Touzeau, Sébastien Anguille, Deeksha Vishwamitra, Ashley Nguyen, Debopriya Ghosh, Elizabeth Shearin, Katherine Thornton, Damiette Smit, Hang Quach

Blood (2023) 142 (Supplement 1): 1014.

https://doi.org/10.1182/blood-2023-187706

Published: 2023

Journal Articles

Comparison of Fludarabine/Cyclophosphamide Vs Bendamustine As Lymphodepleting Regimen for CAR-T: A Safety and Efficacy Analysis in Patients with Relapsed/ Refractory Multiple Myeloma

Sarvarinder Kaur Gill, Noa Biran, Pooja Phull, Sukhdeep Kaur, Hyung C Suh, Christina Cho, Michele L. Donato, Scott D Rowley, David H. Vesole, David S. Siegel, Harsh Parmar

Blood (2023) 142 (Supplement 1): 6903.

https://doi.org/10.1182/blood-2023-190507

Published: 2023

Journal Articles

Using Next Generation Sequencing of Flow Cytometry CD Markers and Machine Learning As a Replacement to Flow Cytometry Analysis for the Diagnosis of Hematologic Neoplasms

Maher Albitar, Hong Zhang, Andrew Ip, Wanlong Ma, James McCloskey, Katherine Linder, Jeffrey Justin Estella, Jamie Koprivnikar, Noa Biran, David S. Siegel, Ahmad Charifa, Arash Mohtashamian, Andrew L Pecora, Andre Goy

Blood (2023) 142 (Supplement 1): 3654.

https://doi.org/10.1182/blood-2023-187041

Published: 2023

Journal Articles

Teclistamab Demonstrates Clinical Activity in Real-World Patients Ineligible for the Pivotal Majestec-1 Trial

Beth Gordon, Lindsay Fogel, Gaurav Varma, Mateo Mejia Saldarriaga, Jaeil Ahn, Adolfo Aleman, Jessica Caro, Xiaoyi Chen, Jorge Monge, Harsh Parmar, David Kaminetzky, Tibor Moskovits, David S. Siegel, Gareth J. Morgan, Ruben Niesvizky, Noa Biran, Faith E. Davies

Blood (2023) 142 (Supplement 1): 4741.

https://doi.org/10.1182/blood-2023-181304

Published: 2023

Journal Articles

Single-Center Experience of Carfilzomib-Based Combinations for Patients with Lymphoplasmacytic Lymphoma

Harsh Parmar, Noa Biran, Pooja Phull, David H. Vesole, David S. Siegel

Blood (2023) 142 (Supplement 1): 1684.

https://doi.org/10.1182/blood-2023-190155

Published: 2023

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Targeted interferon therapy with modakafusp alfa for relapsed or refractory multiple myeloma

Enhanced Prognostic Value of the SKY92 Classifier over High-Risk Cytogenetic Aberrations in Multiple Myeloma: Results from the Prommis Real-World Study

Phase 2 Registrational Study of Anitocabtagene Autoleucel for the Treatment of Patients with Relapsed and/or Refractory Multiple Myeloma: Preliminary Results from the IMMagine-1 Trial

Efficacy and Safety of Selinexor, Pomalidomide, and Dexamethasone (SPd) for Treatment of Patients with Relapsed or Refractory Multiple Myeloma (RRMM)

Phase II Study of Isatuximab, and Weekly Carfilzomib + Dexamethasone in Relapsed and Refractory Multiple Myeloma (RRMM)

Real World Outcomes of Multiple Myeloma Patients Who Underwent Apheresis for Planned Chimeric Antigen Receptor (CAR) T Cell Therapy: A Single Center Experience

Establishing a Distinct Cytokine Signature for Multiple Myeloma Using Bone Marrow RNA and Peripheral Blood Cell-Free RNA (cfRNA)

Clonotype-Naïve Detection of Clonality in Patients Suspected of Having Multiple Myeloma or Monoclonal Gammopathy Using Peripheral Blood Cell-Free RNA (cfRNA)

Delayed Neurotoxicity after CAR-T in Multiple Myeloma: Results from a Global IMWG Registry

Real World Outcomes with Talquetamab, a T-Cell-Redirecting GPRC5D Bispecific Antibody: A Single Center Experience for Relapsed/ Refractory Multiple Myeloma (RRMM)

A Single-Center Experience on the Safety and Efficacy of Venetoclax-Based Regimens in Patients with Relapsed/Refractory Multiple Myeloma

A Phase 2b Study of Selinexor in Combination with Pomalidomide in Patients with Pomalidomide-Refractory Multiple Myeloma

Repurposing DNA Methyltranferase Inhibitors As Epigenetic Priming Agents for T Cell Directed Therapies in Multiple Myeloma

Comparative Efficacy and Safety of Ciltacabtagene Autoleucel and Idecabtagene Vicleucel in Real-World Relapsed/Refractory Multiple Myeloma: A Retrospective Intention-to-Treat Analysis

Unveiling the Discrepancy in Multiple Myeloma Risk Classification between Clinical Practice and SKY92 Test and the Impact on Survival

Talquetamab + Pomalidomide in Patients with Relapsed/Refractory Multiple Myeloma: Safety and Preliminary Efficacy Results from the Phase 1b MonumenTAL-2 Study

Comparison of Fludarabine/Cyclophosphamide Vs Bendamustine As Lymphodepleting Regimen for CAR-T: A Safety and Efficacy Analysis in Patients with Relapsed/ Refractory Multiple Myeloma

Using Next Generation Sequencing of Flow Cytometry CD Markers and Machine Learning As a Replacement to Flow Cytometry Analysis for the Diagnosis of Hematologic Neoplasms

Teclistamab Demonstrates Clinical Activity in Real-World Patients Ineligible for the Pivotal Majestec-1 Trial

Single-Center Experience of Carfilzomib-Based Combinations for Patients with Lymphoplasmacytic Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only